05/13/22 4:00 PMNasdaq : ZSAN earningslow floatZosano Pharma Reports First Quarter 2022 Financial ResultsZosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2022. All share and per share information included in these financial results andRHEA-AInegative
04/29/22 4:00 PMNasdaq : ZSAN low floatZosano Pharma Provides Corporate UpdateZosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today provided a corporate update. On April 14, 2022, the Food and Drug Administration granted Zosano a twelve-month extension to April 20, 2023 to resubmit itsRHEA-AIneutral
04/11/22 8:00 AMNasdaq : ZSAN low floatZosano Pharma Announces Reverse Stock Split Effective TodayZosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its Board of Directors has approved a 1-for-35RHEA-AIneutral
03/17/22 4:05 PMNasdaq : ZSAN earningslow floatZosano Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial ResultsZosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and year ended December 31, 2021, as well as business updates. “We are in discussions with the FDA toRHEA-AIneutral
02/08/22 9:55 PMNasdaq : ZSAN offeringlow floatZosano Pharma Announces Pricing of $15.4 Million Public Offering of Common Stock and WarrantsZosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 51,250,000 units, each consisting of one share of common stock and oneRHEA-AIneutral
02/08/22 4:10 PMNasdaq : ZSAN offeringlow floatZosano Pharma Announces Proposed Public Offering of Common Stock and WarrantsZosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced that it is commencing an underwritten public offering of units consisting of shares of common stock and warrants to purchase common stock. All ofRHEA-AIneutral
01/05/22 12:01 PMNasdaq : ZSAN clinical triallow floatCORRECTION - Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of a Trivalent Influenza Vaccine Formulated on its Transdermal Microneedle System Versus an Intramuscular Injection of the Vaccine at a Higher DoseIn a press release published under the same headline today by Zosano Pharma Corporation (Nasdaq:ZSAN), a measurement was incorrectly stated as grams, not micrograms. The measurements ofRHEA-AIneutral
01/05/22 9:20 AMNasdaq : ZSAN clinical triallow floatZosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of a Trivalent Influenza Vaccine Formulated on its Transdermal Microneedle System Versus an Intramuscular Injection of the Vaccine at a Higher DoseZosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the publication of Phase 1 clinical trial data in an article titled, “ ImmunogenicityRHEA-AIneutral
12/13/21 4:30 PMNasdaq : ZSAN managementlow floatZosano Pharma Announces Changes to Board of Directors; Appoints Cross Functional Business Executive Elaine M. YangZosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced changes to its board of directors, including the appointment of Elaine M. Yang. “We are pleased to welcome Elaine, a high caliber executive, toRHEA-AIneutral
11/29/21 9:45 PMNasdaq : ZSAN low floatZosano Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the Board of Directors granted a stock option to purchase 220,000 shares of Zosano’s common stock to a new employee as an inducement award.RHEA-AIneutral